Research outputs per year
Research outputs per year
Description
The objective of this trial is to assess the effectiveness and safety of L-theanine (an amino acid constituent of green tea [Camellia sinensis]) as an adjunctive therapy to treat GAD by conducting a phase II double-blind randomised controlled trial. It is hypothesised that L-theanine will be superior to placebo in reducing anxiety in participants with GAD.
The dataset relates to the clinical trial ACTRN12616000759493 L-Theanine in the Adjunctive Treatment of Generalised Anxiety Disorder:
A Double-Blind Randomised Placebo-Controlled Trial.
This data cannot be shared publicly due to ethics approval conditions.
To discuss this data, please contact the NICM Health Research Institute [email protected].
The dataset relates to the clinical trial ACTRN12616000759493 L-Theanine in the Adjunctive Treatment of Generalised Anxiety Disorder:
A Double-Blind Randomised Placebo-Controlled Trial.
This data cannot be shared publicly due to ethics approval conditions.
To discuss this data, please contact the NICM Health Research Institute [email protected].
| Date made available | 1 Apr 2025 |
|---|---|
| Publisher | Western Sydney University |
| Date of data production | 12 Sept 2017 - 30 Jun 2018 |
Research output
- 1 Article
-
L-theanine in the adjunctive treatment of generalized anxiety disorder : a double-blind, randomised, placebo-controlled trial
Sarris, J., Byrne, G. J., Cribb, L., Oliver, G., Murphy, J., Macdonald, P., Nazareth, S., Karamacoska, D., Galea, S., Short, A., Ee, C., Birling, Y., Menon, R. & Ng, C. H., 2019, In: Journal of Psychiatric Research. 110, p. 31-37 7 p.Research output: Contribution to journal › Article › peer-review
65 Citations (Scopus)
Cite this
- DataSetCite